LifeVantage Reports Steep Q3 Revenue & Profit Declines, Lowers Guidance Amidst Operational Challenges

summarizeSummary

LifeVantage reported significantly weaker-than-anticipated Q3 fiscal 2026 financial results, with substantial declines in revenue and profitability, and lowered its full-year guidance, despite increasing its quarterly dividend.

check_boxKey Events · Earnings and Guidance · LFVN

• Significant Revenue Decline

  Third-quarter revenue decreased 25.2% year-over-year to $43.7 million, with Americas revenue down 28.9% and Asia/Pacific & Europe revenue down 7.7%.

• Sharp Profitability Drop

  Diluted earnings per share fell 57.7% to $0.11, and Adjusted EBITDA decreased 50% to $3.2 million compared to the prior year period.

• Lowered Fiscal Year Guidance

  The company anticipates fiscal 2026 revenue, adjusted EBITDA, and adjusted EPS to be at the lower end of its previously issued guidance range.

• Dividend Increase Amidst Weakness

  LifeVantage declared an 11.1% increase in its quarterly cash dividend to $0.05 per common share, despite the poor financial performance.

auto_awesomeAnalysis · LFVN · Life Sciences

LifeVantage continues to face significant operational headwinds, as evidenced by the substantial year-over-year declines across all key financial metrics. The 25.2% drop in revenue, coupled with over 50% reductions in diluted EPS and Adjusted EBITDA, indicates a deteriorating financial position. The inventory obsolescence charge and the decision to guide towards the lower end of previous fiscal year expectations further underscore these challenges. While the company increased its dividend and continued its share repurchase program, these actions are largely overshadowed by the severe operational underperformance. Investors should be highly concerned about the company's ability to stabilize and reverse these negative trends.